Every two years, the Epilepsy Foundation holds its Pipeline Conference to bring together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation, and product development. This exciting meeting provides a forum for surveying new therapies in development, exploring future advancements, and encouraging collaborations and partnerships.
This year’s Pipeline Conference will take place February 22-23, 2018, at the Westin St. Francis hotel in San Francisco, California. This conference will also feature a Community Day on Saturday, February 24th, where people living with epilepsy and their family, friends, and advocates gather for a day of learning, support, and networking.
Speakers and attendees will include
- emerging biotech and medical technology companies,
- major pharmaceutical and device companies, and
- researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.
Draft Conference Agenda
Day 1 – Thursday, February 22, 2018
Welcome and Overview
Session I: Technology in Epilepsy: Changing Trials and Therapeutics
- Seizure Diary – John Hixson MD, Associate Professor, University of California-San Diego
- Seizure Prediction/Gauge – Gregory Worrell MD, PhD, Professor of Neurology, Mayo Clinic, Rochestor, Minnesota
- Seizure Detection Device – Robert Fisher MD, PhD, Maslah Saul Professor, Department of Neurology, Standford University Medical Center
- Panel Discussion
Session II: Pre-Clinical Drug Pipeline
- Propofol – Michael Rogawski MD, PhD, EpaleX
- 2DG – Thomas Sutula MD, PhD, NeuroGenomeX, Inc.
- TAK935/OV935 – Mahnaz Asgharnejad PharmD, Ovid/Takeda
- Adenosine-Augmentation Therapies – Deltev Boison PhD, R.S. Dow Neurobiological Laboratoires and Legacy Research Institute
- Pre-clinical Padsevonil – Rafal Kaminski MD, PhD, Senior Director and Head of Epilepsy, UCB Pharma
- Injectable Diazepam: XeriJect™ – Steven Prestrelski PhD, Xeris
Session III: Epilepsy development – Regulatory and financing considerations: How to get your investment and how to get your investment to pay off
- Talk 1: Will epilepsy drugs be able to be reimbursed without comparative data showing superiority, and if you need comparative data, how do you get it?
- How to make a difference: The role of comparative data in AED development: Konrad Werhahn MD, Senior Medical Director, Global Head Clinical Strategy, Seizure Freedom Mission, Neurology, UCB
- Payer Perspective
- If comparative superiority data is needed, how is it acquired?: Daniel Freedman MD, Associate Professor, Department of Neurology, NYU
- Epilepsy Therapy Screening Program (ETSP)/National Institute of Neurological Disorders and Strokes (NINDS): John Kehne PhD, Program Director, ETSP/NINDS
- Panel Discussion
- Orphan versus broad market development
- Dr. Jeremy Levin BChir, MB, DPhil, Chairman of the Board of Directors and CEO, Ovid Therapeutics
- Ms. Terri Sebree, President, Zynerba Pharmaceuticals
- Panel Discussion
- Posters: SUDEP 2nd Milestone winners & 2017 Shark Tank winners
Session IV: Early Stage Device Pipeline
Session V: Regulatory Requirements for Seizures/Epilepsy Devices
- Q & A
- Update by Jacqueline French MD, Chief Scientific Officer, Epilepsy Foundation
- Jonas Duun-Henriksen PhD, Senior Scientific Researcher at UNEEG medical A/S: 24/7 Portable, ultra-long term EEG Recording device won $75,000 in the audience vote for the People’s Choice Award.
- Maysaa Basha MD, Associate Professor in the Department of Neurology at Wayne State University School of Medicine: The Sound of Seizures: Auto-triggered seizure detection won $75,000 awarded by the judges.
- Paula Gomez PhD, CEO of Epistemic, and Hilda A. Cerdeira PhD, Fellow of the America Physical Society: Device for epileptic seizure prediction won $50,000 awarded by the judges.
Day 2 – Friday, February 23, 2018
Patient Video / Research & New Therapies Highlight
Session VI: Social Innovation and Power of Partnerships
- The Epilepsy Foundation – Brandy Fureman PhD, Vice President of Research and New Therapies, Epilepsy Foundation
- The Epilepsy Study Consortium – Jacqueline French MD
- Citizens United for Research in Epilepsy (CURE): Infantile Spasms Initiative – Laura Lubbers PhD, Chief Scientific Officer, CURE
- Tuberous Sclerosis Alliance: Preclinical Trial Consortium – Steve Roberds PhD, Chief Scientific Officer, Tuberous Sclerosis Alliance
- Pediatric Epilepsy Research Foundation (PERC): Advancing Pediatric Trials – Kelly Knupp MD, Children’s Hospital Colorado
- Panel Discussion
Session VII: Registries
- Human Epilepsy Project (HEP & HEP 2) – Daniel Lowenstein MD, Executive Vice Chancellor and Provost, University of California-San Diego
- Rare Epilepsy Network (REN)
- Registry Patient
- Panel Discussion / Q & A
Session VIII: Clinical Devices/Other
- Embrace Seizure Detection Watch – Matteo Lai, Co-Founder and CEO, Empatica
- Epilog, Wearable Seizure Diary – Mark Lehmkuhle PhD, Epitel, Inc.
Session IX: Research Roundtable for Epilepsy
Session X: Clinical Drugs
- BIS-001 ER – Stephen D. Collins MD, PhD, Biscayne/Insero
- ZYN002, CBD Gel – Donna Gutterman PharmD, Zynerba
- NRP2945 – Frank Sieg PhD, Chief Scientist, CuroNZ Ltd.
- ZX008, Low-Dose Fenfluramine – Glen Morrison PhD, Zogenix
- Staccato Alprazolam – Jouko Isojarvi MD, PhD, Engage Therapeutics Inc.
- XEN1101 – Y. Paul Goldberg MBChB, PhD, FRCPC, Xenon
- Ganalaxone – Lorianne K. Masuoka MD, Chief Medical Officer, Marinus
- UX007 – Melanie Brandabur MD, Ultragenyx
- NRL-1, Intranasal Diazepam – Craig Chambliss, President & CEO, Neurelis
- Clinical Padsevonil – Pierandrea Muglia MD, Vice President & Head Neuroscience Discovery Medicine, UCB Pharma
- PF-06372865 – Rachel Gurrell, Clinical Lead, Early Clinical Development, Pfizer
- TIL-TC150 – Dr. Bláthnaid McCoy MB BCh, BAO, MRCPI, CSCSN (EEG), MSc, Program Director, Neurology Residency & Epilepsy Fellowship Programs; Assistant Professor of Pediatrics, University of Toronto; Pediatric Neurologist, Hospital for Sick Children Toronto, Tillray
- Brexanolone – Paul Miller MS, Sage